BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF). CEO Dr. Ahmad Doroudian tells Proactive the Vancouver, Canada-based group has obtained the first set of positive in vivo pharmacokinetic data confirming the bioavailability of its lead compound BETR-001 in its pre-clinical study. Doroudian says these results provide strong evidence that BETR-001 can reach the brain and achieve the desired therapeutic range. He adds the group is 3 months away from completing an IND package to submit to the FDA.
BetterLife Pharma says it has confirmed bioavailability of BETR-001 compound in pre-clinical study
